| Literature DB >> 23825649 |
Karina Standahl Olsen1, Christopher Fenton, Livar Frøyland, Marit Waaseth, Ruth H Paulssen, Eiliv Lund.
Abstract
High blood concentrations of n-6 fatty acids (FAs) relative to n-3 FAs may lead to a "physiological switch" towards permanent low-grade inflammation, potentially influencing the onset of cardiovascular and inflammatory diseases, as well as cancer. To explore the potential effects of FA ratios prior to disease onset, we measured blood gene expression profiles and plasma FA ratios (linoleic acid/alpha-linolenic acid, LA/ALA; arachidonic acid/eicosapentaenoic acid, AA/EPA; and total n-6/n-3) in a cross-section of middle-aged Norwegian women (n = 227). After arranging samples from the highest values to the lowest for all three FA ratios (LA/ALA, AA/EPA and total n-6/n-3), the highest and lowest deciles of samples were compared. Differences in gene expression profiles were assessed by single-gene and pathway-level analyses. The LA/ALA ratio had the largest impact on gene expression profiles, with 135 differentially expressed genes, followed by the total n-6/n-3 ratio (125 genes) and the AA/EPA ratio (72 genes). All FA ratios were associated with genes related to immune processes, with a tendency for increased pro-inflammatory signaling in the highest FA ratio deciles. Lipid metabolism related to peroxisome proliferator-activated receptor γ (PPARγ) signaling was modified, with possible implications for foam cell formation and development of cardiovascular diseases. We identified higher expression levels of several autophagy marker genes, mainly in the lowest LA/ALA decile. This finding may point to the regulation of autophagy as a novel aspect of FA biology which warrants further study. Lastly, all FA ratios were associated with gene sets that included targets of specific microRNAs, and gene sets containing common promoter motifs that did not match any known transcription factors. We conclude that plasma FA ratios are associated with differences in blood gene expression profiles in this free-living population, and that affected genes and pathways may influence the onset and progression of disease.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23825649 PMCID: PMC3692510 DOI: 10.1371/journal.pone.0067270
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of the 227 women in the study populationa.
| Characteristic | Mean or frequency |
| Age | 55.6±3.5 |
| BMI | 25.5±4.4 |
| Smoking | 59 (26%) |
| Fasting | 13 (7%) |
| Time since meal (h) | 2.7±3.7 |
| n-3 supplements | 130 (59%) |
| NSAIDs | 20 (9%) |
| Cardiovascular medication | 30 (13%) |
| HRT | 39 (17%) |
| LA/ALA | 51.9±17.8 |
| AA/EPA | 4.3±2.8 |
| n-6/n-3 | 6.1±2.0 |
Format for age, BMI, time since meal, and FA ratios: mean (standard deviation). Format for smoking, fasting, supplements and medication: frequency (percent). Missing: BMI: 3, smoking: 1, fasting: 27, n-3 supplements: 5.
Abbreviations: AA: arachidonic acid, ALA: alpha-linolenic acid, BMI: body mass index, EPA: eicosapentaenoic acid, h: hours, HRT: hormone replacement therapy, LA: linoleic acid, n-3 supplements: any combination of n-3 capsules/oils, cod liver oil or both, NSAIDs: non-steroidal anti-inflammatory drugs.
Characteristics of the highest and lowest fatty acid ratio decilesa.
| LA/ALA ratio | AA/EPA ratio | n6/n3 ratio | |||||||
| Highest decile | Lowest decile | p | Highest decile | Lowest decile | p | Highest decile | Lowest decile | p | |
| Age | 55±3.7 | 55±3.3 | 0.97 | 54±3.5 | 57±3.0 | <0.01 | 53±3.3 | 57±3.2 | <0.01 |
| BMI | 24±2.8 | 26±3.6 | 0.17 | 24±4.0 | 23±2.5 | 0.4 | 23±3.8 | 24±4.0 | 0.47 |
| Smoking | 8 (35%) | 5 (22%) | 0.51 | 8 (36%) | 2 (9%) | 0.04 | 8 (36%) | 3 (13%) | 0.14 |
| Fasting | 3 (16%) | 1 (5%) | 0.33 | 2 (10%) | 0 | 0.23 | 0 | 0 | NA |
| Time since meal (h) | 3.7±5.1 | 1.9±2.6 | 0.24 | 3.2±4.1 | 1.9±1.7 | 0.18 | 1.7±1.2 | 2.2±2.4 | 0.72 |
| n-3 suppl. | 12 (52%) | 14 (61%) | 0.77 | 3 (14%) | 21 (91%) | <0.01 | 4 (18%) | 22 (96%) | <0.01 |
| NSAIDs | 2 (9%) | 0 | 0.49 | 4 (17%) | 1 (4%) | 0.35 | 5 (22%) | 3 (13%) | 0.70 |
| Cardiovascular medication | 3 (13%) | 5 (22%) | 0.70 | 4 (17%) | 0 | 0.11 | 2 (9%) | 1 (4%) | 1.00 |
| HRT | 5 (22%) | 2 (9%) | 0.41 | 9 (17%) | 3 (13%) | 0.09 | 8 (35%) | 3 (13%) | 0.07 |
| LA/ALA | 86.8±14.2 | 26±5.0 | <0.01 | 61.0±23.9 | 46.4±16.4 | 0.02 | 62.1±23.9 | 45.5±15.0 | 0.01 |
| AA/EPA | 4.9±3.1 | 3.2±1.9 | 0.02 | 10.4±2.8 | 1.3±0.2 | <0.01 | 9.2±2.8 | 1.5±0.5 | <0.01 |
| n-6/n-3 | 6.9±2.3 | 5.0±1.6 | <0.01 | 9.5±1.8 | 3.4±0.8 | <0.01 | 10.0±1.4 | 3.1±0.5 | <0.01 |
Decile n = 23. Subgroups may not total 227 due to missing values.
Abbreviations: AA: arachidonic acid, ALA: alpha-linolenic acid, BMI: body mass index, EPA: eicosapentaenoic acid, h: hours, HRT: hormone replacement therapy, LA: linoleic acid, n-3 suppl.: any combination of n-3 capsules/oils, cod liver oil or both, NSAIDs: non-steroidal anti-inflammatory drugs.
Number of differentially expressed genes (t-tests, p≤0.01).
| FA ratio | Differentially expressed | Up-regulated | Down-regulated |
| LA/ALA | 315 | 168 | 147 |
| AA/EPA | 72 | 35 | 37 |
| n-6/n-3 | 125 | 46 | 79 |
Abbreviations: AA: arachidonic acid, ALA: alpha-linolenic acid, EPA: eicosapentaenoic acid, FA: fatty acid, LA: linoleic acid.
Top 10 up- and down-regulated genes associated with LA/ALA ratio (p≤0.01)a.
| Gene symbol | Gene name | ABI probe ID | Entrez gene ID | Mean difference |
| HDC | Histidine decarboxylase | 194873 | 3067 | 1.41 |
| CPA3 | Carboxypeptidase A3 (mast cell) | 100989 | 1359 | 1.36 |
| TCHHL1 | Trichohyalin-like 1 (basalin, S100 calcium-binding protein A17) | 132590 | 126637 | 1.20 |
| MYBPHL | Myosin binding protein H-like | 201601 | 343263 | 1.18 |
| FcER1B | FC epsilon receptor I beta-chain (MS4A2) | 182643 | 2206 | 1.00 |
| ANPEP | Alanyl (membrane) aminopeptidase (CD13) | 102558 | 290 | 0.64 |
| GLT1D1 | Glycosyltransferase 1 domain-containing protein 1 | 185381 | 144423 | 0.63 |
| ZNF558 | Zinc finger protein 558 | 124882 | 148156 | 0.63 |
| SLC22A9 | Solute carrier family 22 (organic anion/cation transporter) 9 | 206544 | 114571 | 0.62 |
| FABP4 | Fatty acid binding protein 4, adipocyte | 150137 | 2167 | 0.61 |
| IFIT1L | Interferon-induced protein with tetratricopeptide repeats 1B | 112888 | 439996 | −0.75 |
| MINPP1 | Multiple inositol polyphosphate phosphatase 1 | 188640 | 9562 | −0.70 |
| OR2W3 | Olfactory receptor 2W3 | 702434 | 343171 | −0.70 |
| FAM63B | Family with sequence similarity 63, member B | 161432 | 54629 | −0.69 |
| GFI1 | Growth factor independent 1 transcription repressor (ZNF163) | 121984 | 2672 | −0.69 |
| MATR3 | Matrin 3 | 229698 | 9782 | −0.66 |
| SNCA | Synuclein, alpha (non A4 comp. of amyloid precursor) | 170285 | 6622 | −0.63 |
| MYBL1 | V-myb myeloblastosis viral oncogene homolog (avian)-like 1 | 207803 | 4603 | −0.63 |
| NR2C2AP | Nuclear receptor 2C2-associated protein | 211955 | 126382 | −0.59 |
| KLRG1 | Killer cell lectin-like receptor subfamily G, member 1 | 188801 | 10219 | −0.58 |
Complete lists of differentially expressed genes (p≤0.01) are given in Supplemental Table S2.
Abbreviations: ABI: Applied Biosystems, ALA: alpha-linolenic acid, LA: linoleic acid.
Top 10 up- and down-regulated genes associated with total n-6/n-3 ratio (p≤0.01)a.
| Gene symbol | Gene name | ABI probe ID | Entrez gene ID | Mean difference |
| SERPINB9 | Serpin peptidase inhibitor, clade B (ovalbumin), member 9 (PI9) | 113696 | 5272 | 0.57 |
| MSMO1 | Methylsterol monooxygenase 1 (SC4MOL) | 157577 | 6307 | 0.56 |
| SNAP23 | Synaptosomal-associated protein, 23 kD | 188605 | 8773 | 0.55 |
| CACNB1 | Calcium channel, voltage-dependent, beta 1 subunit | 206077 | 782 | 0.51 |
| SLC30A5 | Solute carrier family 30 (zinc transporter), member 5 | 209725 | 64924 | 0.51 |
| ISLR | Immunoglobulin superfamily containing leucine-rich repeat | 103786 | 3671 | 0.48 |
| CCDC78 | Coiled-coil domain containing 78 | 171388 | 124093 | 0.48 |
| ACOT13 | Acyl-coenzyme A thioesterase 13 (THEM2) | 137024 | 55856 | 0.46 |
| C12orf43 | Chromosome 12 open reading frame 43 | 230584 | 64897 | 0.46 |
| DHX34 | DEAH (Asp-Glu-Ala-His) box polypeptide 34 | 210135 | 9704 | 0.45 |
| PRAC | Prostate cancer susceptibility candidate (C17orf92) | 177570 | 84366 | −0.64 |
| HGS | Hepatocyte growth factor-regulated tyrosine kinase substrate | 118384 | 9146 | −0.62 |
| USP5 | Ubiquitin specific protease 5 (isopeptidase T) | 195536 | 8078 | −0.60 |
| PLA2G6 | Phospholipase A2, group VI (cytosolic, calcium-independent) | 149260 | 8398 | −0.55 |
| MRPL55 | Mitochondrial ribosomal protein L55 | 216047 | 128308 | −0.55 |
| SCARF1 | Scavenger receptor class F member 1 | 172281 | 8578 | −0.54 |
| OSBP2 | Oxysterol-binding protein 2 | 148957 | 23762 | −0.50 |
| ASCC2 | Activating signal cointegrator 1 complex subunit 2 (p100) | 186213 | 84164 | −0.50 |
| NELF | Nasal embryonic luteinizing hormone-releasing hormone factor | 159936 | 26012 | −0.47 |
| ABCG1 | ATP-binding cassette, sub-family G (WHITE), member 1 | 210662 | 9619 | −0.47 |
Complete lists of differentially expressed genes (p≤0.01) are given in Supplemental Table S4.
Abbreviations: ABI: Applied Biosystems.
Significant overlaps between differentially expressed genes and reported gene sets in MSigDBa.
| FA ratio | Gene Set Name | K | k | k/K |
| LA/ALA | ||||
| KRCTCNNNNMANAGC Unknown | 60 | 6 | 10% | |
| Immune response | 232 | 11 | 5% | |
| Reactome Packaging of telomere ends | 49 | 5 | 10% | |
| Reactome Telomere maintenance | 77 | 6 | 8% | |
| Immune system process | 326 | 12 | 4% | |
| Kegg nitrogen emtabolism | 23 | 3 | 13% | |
| RYTAAWNNNTGAY Unknown | 53 | 4 | 8% | |
| Locomotory behavior | 91 | 5 | 5% | |
| Positive regulation of defence response | 10 | 2 | 20% | |
| Response to external stimulus | 306 | 10 | 3% | |
| Reactome RNA Pol I promoter opening | 59 | 4 | 7% | |
| Reactome DNA strand elongation | 31 | 3 | 10% | |
| Hydrolase activity acting on ester bonds | 264 | 9 | 3% | |
| Reactome Unwinding of DNA | 11 | 2 | 18% | |
| Cofactor transport | 11 | 2 | 18% | |
| Reactome Signal attenuation | 11 | 2 | 18% | |
| AA/EPA | ||||
| Phospholipid transporter activity | 12 | 2 | 17% | |
| Lipid transporter activity | 27 | 2 | 7% | |
| Nuclear body | 33 | 2 | 6% | |
| TCTAGAG, MIR-517 | 37 | 2 | 5% | |
| Kegg ABC Transporters | 44 | 2 | 5% | |
| Total n-6/n-3 | ||||
| Biocarta Mitochondria pathway | 21 | 2 | 14% | |
| Reactome Intrinsic pathway for apoptosis | 29 | 3 | 4% | |
| Apoptotic program | 60 | 2 | 10% | |
| CCCAGAG,MIR-326 | 135 | 4 | 3% | |
| SCGGAAGY_V$ELK1_02 | 822 | 6 | 2% | |
| Post Golgi vesicle mediated transport | 14 | 2 | 7% | |
| Intracellular transport | 271 | 5 | 2% |
The table is sorted by p-values with the lowest first, all p-values<0.01. Number of genes submitted for comparison was 184 for LA/ALA, 36 for AA/EPA, and 65 for n-6/n-3. Gene sets significant at p<0.05 are provided in Supplemental Tables S5–S7.
Abbreviations: AA: arachidonic acid, ALA: alpha-linolenic acid, EPA: eicosapentaenoic acid, FA: fatty acid, K: number of genes in gene set, k: number of genes in overlap, LA: linoleic acid.
Gene Set Enrichment Analysis.
| FA ratio | Geneset | Size | Title | NES | NOM p | FDR q |
| LA/ALA | ||||||
| BP00117 | 26 | Jak-STAT cascade | 1.79 | 0.01 | 0.23 | |
| GO_0006913 | 30 | Nucleocytoplasmic transport | −1.80 | 0.01 | 0.16 | |
| GO_0051169 | 30 | Nuclear transport | −1.80 | 0.01 | 0.16 | |
| GO_0051188 | 25 | Cofactor biosynthetic process | −1.61 | 0.03 | 0.22 | |
| GO_0051168 | 17 | Nuclear export | −1.61 | 0.03 | 0.24 | |
| AA/EPA | ||||||
| BP00101 | 19 | Sulfur metabolism | −2.07 | <0.01 | <0.01 |
There were no significantly enriched gene sets related to n-6/n-3.
Abbreviations: AA: arachidonic acid, ALA: alpha-linolenic acid, EPA: eicosapentaenoic acid, FA: fatty acid, FDR: false discovery rate, LA: linoleic acid, NES: normalized enrichment score, NOM p: nominal p-value.
Top 10 up- and down-regulated genes associated with AA/EPA ratio (p≤0.01)a.
| Gene symbol | Gene name | ABI probe ID | Entrez gene ID | Mean difference |
| ABCB9 | ATP-binding cassette, sub-family B (MDR/TAP), member 9 | 155893 | 23457 | 0.68 |
| ZNF354A | Zinc finger protein eZNF (transcription factor 17) | 214609 | 6940 | 0.64 |
| ENTPD4 | Ectonucleoside triphosphate diphosphohydrolase 4 (LYSAL1) | 226738 | 9583 | 0.56 |
| ZCCHC2 | Zinc finger, CCHC domain-containing protein 2 | 154456 | 54877 | 0.51 |
| RNMTL1 | RNA methyltransferase-like protein 1 | 135382 | 55178 | 0.51 |
| GRIN2C | Glutamate receptor, ionotropic, N-methyl D-aspartate 2C | 194729 | 2905 | 0.47 |
| PODNL1 | Podocan-like 1 | 146598 | 79883 | 0.47 |
| CCL24 | Chemokine (C-C motif) ligand 24 | 128049 | 6369 | 0.44 |
| RNF157 | Ring finger protein 157 | 212544 | 114804 | 0.40 |
| C20orf26 | Chromosome 20 open reading frame 26 | 150962 | 26074 | 0.35 |
| HLA-DQA1 | Major histocompatibility complex, class II, DQ alpha 1 | 170258 | 3117 | −1.04 |
| LMOD2 | Leiomodin 2 (cardiac) | 187222 | 442721 | −0.80 |
| APLP2 | Amyloid beta (A4) precursor-like protein 2 | 223157 | 334 | −0.74 |
| GPR97 | G protein-coupled receptor 97 | 112591 | 222487 | −0.61 |
| FBXO17 | F-box protein 17 | 163400 | 115290 | −0.46 |
| TMEM132B | Transmembrane protein 132B | 167812 | 114795 | −0.44 |
| PTK2 | Protein-tyrosine kinase 2 (FAK) | 128624 | 5747 | −0.44 |
| OSBP2 | Oxysterol-binding protein 2 | 148957 | 23762 | −0.43 |
| C4orf22 | Chromosome 4 open reading frame 22 | 164838 | 255119 | −0.39 |
| ABCG1 | ATP-binding cassette, sub-family G (WHITE), member 1 | 210662 | 9619 | −0.39 |
Complete lists of differentially expressed genes (p≤0.01) are given in Supplemental Table S3.
Abbreviations: AA: arachidonic acid, ABI: Applied Biosystems, EPA: eicosapentaenoic acid.